## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and conclusions as presented in the abstract, without access to full methods, figures, or supplementary data
- **Shared manuscript claim summary** The authors propose that curcumin binds to and stabilizes the G-quadruplex (Pu-27) in the NHE III1 element of the c-MYC promoter, thereby repressing MYC transcription and translation, and inducing apoptosis in metastatic triple negative breast cancer cells (MDA-MB-231) via a proposed MYC-E2F-1-BCL-2 axis.
- **Visible evidence base** Abstract text only; no figures, tables, or methods sections provided
- **Missing materials affecting confidence** Full experimental details, biophysical data (e.g., CD, ITC, FRET), molecular docking and MD simulation parameters, ChIP assay protocols and quantification, Western blot and qPCR data, apoptosis assays, statistical analyses, and any control experiments

## Reviewer
- **Overall assessment** The abstract presents a plausible and potentially interesting hypothesis that curcumin stabilizes the MYC G-quadruplex to downregulate MYC and trigger apoptosis. However, the evidence base is entirely descriptive and lacks quantitative data, controls, and methodological detail. The claim of a new apoptotic pathway (MYC-E2F-1-BCL-2 axis) is not substantiated from the abstract alone. The work may be of interest to the biophysics and cancer biology communities, but the current presentation does not establish the case convincingly.
- **Who would be interested in the results, and why** Researchers in G-quadruplex biology, natural product anticancer drug discovery, and MYC-driven cancer therapeutics would be interested. The potential to repurpose curcumin as a MYC silencer via G-quadruplex stabilization is a topical and translational angle.
- **Major strengths** The study addresses a clinically relevant target (c-MYC in TNBC) and uses a multimodal approach (biophysics, in silico, cellular assays, ChIP). The focus on a natural compound with known safety profile adds translational appeal. The proposed mechanism linking G-quadruplex stabilization to apoptosis via a specific axis is conceptually coherent.
- **Major Concerns** The abstract lacks quantitative evidence for G-quadruplex stabilization (e.g., DeltaTm values, binding constants). The claim of a "new pathway" is premature without functional validation (e.g., knockdown or overexpression experiments). The ChIP data are described qualitatively without occupancy changes or statistical significance. No evidence is provided that curcumin's effects are specific to MYC G-quadruplex versus off-target effects. The link between MYC repression and apoptosis via BCL-2 is inferred, not demonstrated.
- **Minor Comments** The abstract would benefit from stating the concentration range of curcumin used and its cytotoxicity profile. The phrase "threshold-level" is vague and should be defined. The role of hnRNPK, NM23-H2, and Nucleolin is mentioned but not explained in terms of mechanism. The abstract should clarify whether the biophysical experiments were done with the Pu-27 sequence alone or in the context of the full NHE III1 element.
- **Technical failings that need to be addressed before the case is established** No quantitative biophysical data (binding affinity, stoichiometry, thermal stability shifts) are provided. No evidence of G-quadruplex specificity (e.g., competition with duplex DNA or other G-quadruplexes). No functional rescue experiments to prove that MYC downregulation is necessary for apoptosis. No statistical analysis or replicates described for cellular assays.
- **Assessment against Nature-style criteria** Originality: Moderate; the concept of G-quadruplex targeting by natural compounds is not new, but the specific combination with a proposed apoptotic axis is somewhat novel. Scientific importance: High for TNBC given the lack of targeted therapies, but the abstract does not yet demonstrate clinical relevance. Interdisciplinary readership: The work spans biophysics, computational chemistry, and cell biology, which could appeal to a broad audience, but the abstract is too specialized in places. Technical soundness: Not assessable from the abstract; key data are missing. Readability for nonspecialists: The abstract is dense and assumes familiarity with G-quadruplex biology and MYC regulation; it would benefit from clearer context and definitions.
- **Recommendation posture** Currently not established from the provided evidence. The hypothesis is interesting, but the abstract does not provide sufficient quantitative or mechanistic support. I would be supportive if the full manuscript includes rigorous biophysical characterization, specificity controls, and functional validation of the proposed pathway.

### Major Concerns

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Evidence quality
- **Claim pointer** "We have observed significantly increased stability of MYC-G Quadruplex and thermodynamic spontaneity of Curcumin-MYC GQ binding with negative DeltaG value."
- **Evidence pointer** Abstract; location not provided
- **Concern** The claim of increased G-quadruplex stability and spontaneous binding is made without any quantitative data, such as melting temperature shifts (DeltaTm), binding constants (Kd), or enthalpy/entropy contributions. The negative DeltaG value is mentioned but not contextualized with error bars or comparison to controls.
- **Why it matters** Without quantitative biophysical parameters, the reader cannot assess the strength or specificity of curcumin's interaction with the MYC G-quadruplex. This is the foundational claim of the study, and its lack of support undermines the entire mechanistic narrative.
- **Resolution test** Provide a table or figure with DeltaTm values from CD or FRET melting assays, a binding isotherm with Kd from ITC or SPR, and a comparison with a non-G-quadruplex control (e.g., duplex DNA or a mutated G-quadruplex sequence).

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Mechanistic validation
- **Claim pointer** "We have concluded that Curcumin binding tends to drive the equilibrium towards stable G-quadruplex formation repressing MYC back to its threshold-level."
- **Evidence pointer** Abstract; location not provided
- **Concern** The conclusion that curcumin drives G-quadruplex formation to repress MYC is based on correlative data (ChIP occupancy changes and expression levels) but lacks causal evidence. The abstract does not show that G-quadruplex stabilization is necessary for MYC repression, nor does it rule out other mechanisms of curcumin action (e.g., off-target transcription factor inhibition).
- **Why it matters** Curcumin is a known pleiotropic agent with many cellular targets. Without a loss-of-function or rescue experiment (e.g., using a G-quadruplex-stabilizing mutant or a curcumin analog that cannot bind G-quadruplex), the specific role of G-quadruplex in MYC repression is not established.
- **Resolution test** Include experiments where the Pu-27 sequence is mutated to disrupt G-quadruplex formation, and show that curcumin's effect on MYC expression is abrogated. Alternatively, use a known G-quadruplex ligand as a positive control and a non-binding curcumin derivative as a negative control.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** Yes
- **Axis** Claim of novelty
- **Claim pointer** "we have also reported a new pathway [MYC-E2F-1-BCL-2-axis] through which Curcumin trigger apoptosis in cancer cells."
- **Evidence pointer** Abstract; location not provided
- **Concern** The claim of a "new pathway" is not supported by the abstract. The abstract only mentions that MYC and BCL-2 are synergistically upregulated in cancer, but no data are shown to demonstrate that curcumin's effect on MYC leads to changes in E2F-1 and BCL-2 expression, or that this axis is functionally required for apoptosis.
- **Why it matters** Claiming a novel pathway requires direct evidence of each component's involvement and their causal relationships. Without such data, the claim is speculative and could mislead readers.
- **Resolution test** Provide Western blot or qPCR data showing changes in E2F-1 and BCL-2 levels upon curcumin treatment, and include functional assays (e.g., E2F-1 knockdown or BCL-2 overexpression) to demonstrate that the axis is necessary for curcumin-induced apoptosis.

### Minor Comments

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Clarity
- **Affected element** "threshold-level"
- **Evidence pointer** Abstract; location not provided
- **Issue** The term "threshold-level" is vague and not defined. It is unclear whether this refers to a specific basal expression level, a statistical threshold, or a functional level.
- **Required correction** Define "threshold-level" operationally, e.g., "the level of MYC expression in non-malignant breast epithelial cells" or "a statistically significant reduction compared to untreated controls."

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Completeness
- **Affected element** ChIP assay description
- **Evidence pointer** Abstract; location not provided
- **Issue** The ChIP assay is mentioned but the occupancy changes of SP1, hnRNPK, NM23-H2, and nucleolin are not quantified or described in terms of direction or magnitude. The reader cannot assess whether these changes are consistent with G-quadruplex stabilization.
- **Required correction** State the direction of occupancy change for each factor (e.g., "SP1 occupancy decreased by X-fold") and provide statistical significance in the full manuscript.

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Specificity
- **Affected element** Curcumin concentration and selectivity
- **Evidence pointer** Abstract; location not provided
- **Issue** The abstract does not specify the concentration range of curcumin used in cellular assays, nor does it address whether the observed effects are specific to MYC G-quadruplex or could be due to general cytotoxicity or off-target binding.
- **Required correction** Include the concentration range and IC50 values for cellular assays, and discuss or provide data on selectivity for G-quadruplex over other nucleic acid structures.

## Risk / unsupported claims
- The claim of "significantly increased stability" of the MYC G-quadruplex is unsupported without quantitative DeltaTm or binding affinity data.
- The claim of a "new pathway" (MYC-E2F-1-BCL-2 axis) is unsupported and speculative based on the abstract alone.
- The conclusion that curcumin "drives the equilibrium towards stable G-quadruplex formation" is not directly evidenced; it is inferred from indirect measurements.
- The relevance of the findings to "metastatic breast cancer cells" is stated but not substantiated with any metastasis-specific assays (e.g., invasion or migration data).